Literature DB >> 33317581

Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.

Timothy Devos1,2, Tatjana Geukens3,4, Alexander Schauwvlieghe5, Kevin K Ariën6, Cyril Barbezange7, Myriam Cleeren3, Veerle Compernolle8, Nicolas Dauby9, Daniël Desmecht10, David Grimaldi11, Bart N Lambrecht5, Anne Luyten12, Piet Maes13, Michel Moutschen10, Marta Romano7, Lucie Seyler14, Michel Toungouz Nevessignsky15, Katleen Vandenberghe12, Johan van Griensven6, Geert Verbeke16, Erika Vlieghe17, Jean Cyr Yombi18, Laurens Liesenborghs13, Peter Verhamme3, Geert Meyfroidt3.   

Abstract

Entities:  

Year:  2020        PMID： 33317581      PMCID： PMC7734912          DOI： 10.1186/s13063-020-04947-2

Source DB:  PubMed          Journal:  Trials        ISSN： 1745-6215            Impact factor:   2.279


× No keyword cloud information.
Correction to: Trials 21, 981 (2020) https://doi.org/10.1186/s13063-020-04876-0 Following publication of the original article [1], we were notified of a typing mistake in one of the author names. Originally published name: Alexander Schauvlieghe. Corrected name: Alexander Schauwvlieghe. The original article has been corrected.
  1 in total

1.  A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.

Authors:  Timothy Devos; Tatjana Geukens; Alexander Schauwvlieghe; Kevin K Ariën; Cyril Barbezange; Myriam Cleeren; Veerle Compernolle; Nicolas Dauby; Daniël Desmecht; David Grimaldi; Bart N Lambrecht; Anne Luyten; Piet Maes; Michel Moutschen; Marta Romano; Lucie Seyler; Michel Toungouz Nevessignsky; Katleen Vandenberghe; Johan van Griensven; Geert Verbeke; Erika Vlieghe; Jean Cyr Yombi; Laurens Liesenborghs; Peter Verhamme; Geert Meyfroidt
Journal:  Trials       Date:  2020-11-27       Impact factor: 2.279
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.